ak002
Showing 1 - 9 of 9
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis Trial in United States (AK002)
Active, not recruiting
- Eosinophilic Gastritis
- +2 more
- AK002
-
Phoenix, Arizona
- +16 more
Jun 21, 2021
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis Trial in United States (AK002, Placebo)
Active, not recruiting
- Eosinophilic Duodenitis
- Eosinophilic Gastroenteritis
- AK002
- Placebo
-
Birmingham, Alabama
- +38 more
Dec 16, 2021
Atopic Dermatitis Trial in United States (AK002, Placebo)
Recruiting
- Atopic Dermatitis
- AK002
- Placebo
-
Birmingham, Alabama
- +47 more
Aug 18, 2022
Eosinophilic Gastritis, Eosinophilic Duodenitis Trial in United States (AK002, Placebo)
Recruiting
- Eosinophilic Gastritis
- Eosinophilic Duodenitis
- AK002
- Placebo
-
Birmingham, Alabama
- +73 more
Dec 9, 2021
Chronic Urticaria Trial in Germany, United States (AK002)
Completed
- Chronic Urticaria
- AK002
-
Edgewater, Florida
- +3 more
May 19, 2020
Eosinophilic Gastritis, Eosinophilic Gastroenteritis Trial in United States (AK002, Placebo)
Completed
- Eosinophilic Gastritis
- Eosinophilic Gastroenteritis
- AK002
- Placebo
-
Phoenix, Arizona
- +20 more
Jun 10, 2020
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis Trial in United States (AK002)
Completed
- Atopic Keratoconjunctivitis
- +2 more
- AK002
-
Palo Alto, California
- +7 more
Aug 28, 2019
Indolent Systemic Mastocytosis Trial in Berlin (AK002)
Completed
- Indolent Systemic Mastocytosis
- AK002
-
Berlin, GermanyCharité - Universitätsmedizin Berlin
Mar 12, 2019
Healthy Trial in Melbourne (AK002, Placebo)
Completed
- Healthy
- AK002
- Placebo
-
Melbourne, AustraliaNucleus Network Limited
Sep 25, 2017